Renee Reimonenq WatsonRenee
Counsel, Commercial Legal
Gilead Sciences, Inc.


Renee is an attorney in the Commercial Legal group at Gilead Sciences, Inc. with responsibility for providing legal support in the areas of managed care contracting, distribution, patient assistance programs and price reporting. Renee received a JD from UC Davis School of Law and BS in Biochemistry from UC San Diego. Prior to joining Gilead in 2013, she was in-house counsel at a drug development company in San Diego.


Renee will be one of the distinguished speakers at the Pharmaceutical Government Pricing and Contracting Conference.


What motivated you to participate in Q1’s event?
The quality of the speakers and timeliness of the subject matter.


What are you most excited about your presentation and/or panel discussion?
Learning how other pharma manufacturers are approaching implementation of the final rule.


Why is the Pharmaceutical Government Pricing & Contracting Conference important to pricing and contracting professionals?
It provides a forum to share ideas on how to best implement the final rule.


Not registered for the Pharmaceutical Government Pricing & Contracting Conference yet? Check out some of the highlighted sessions:

  • Impact of the Amp Final Rule on the 340b Program
    Led by Stephanie Hales, Partner, Sidley Austin LLP
  • Panel: Industry, Legal, & Consulting: Interpretations on Amp Final Rule
    Led by Frank Prybeck of Celgene, Kave Niksefat of Amgen, John Shakow of King & Spalding, Stephanie Hale of Sidley Austin LLP, and John Gould of Arnold & Porter
  • Co Presentation: Medicaid Expansion at the State Level: Research Analysis
    Led by Paula Martins, Director, Government Pricing & Contracting, Valeant Pharmaceuticals and Lisa McNair, Manager, Contracting & Reimbursing, Indivior